Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 1 4Phase 3 3Phase 2 3

Status

Completed 4

Sponsor Class

OTHER 16NIH 4NETWORK 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3

Conditions

Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × etoposide phosphate × Clear all
NCT02964013 2025-10-14

KEYVIBE-001

Merck Sharp & Dohme LLC

Phase 1 Completed
474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT01840579 2021-06-22

MK-3475-011

Merck Sharp & Dohme LLC

Phase 1 Completed
57 enrolled 60 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT00927875 2013-06-03

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Bristol-Myers Squibb

Phase 1 Completed
5 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT00621361 2012-12-17

Phase I Safety and Tolerability Study of Cediranib (RECENTINâ„¢, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

AstraZeneca

Phase 1 Completed
62 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡